Roche Deals With Huge Gantenerumab Curiosity At H1 Update
Anti-Amyloid Beta Therapy Is In Phase III For Alzheimer's
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.
You may also be interested in...
Management updated investors on M&A strategy, US drug pricing reform and R&D investment.
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
Medicare Coverage For Alzheimer’s Treatments Should Have Flexibilities For Labeling Differences, Developers say
Lilly and Genentech express concern that the Centers for Medicare and Medicaid Services will set Medicare coverage parameters for their Alzheimer’s drugs even before all the data is in.